Your browser is no longer supported. Please, upgrade your browser.
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.62 Insider Own4.77% Shs Outstand62.93M Perf Week-18.96%
Market Cap135.01M Forward P/E- EPS next Y-1.96 Insider Trans-0.07% Shs Float58.99M Perf Month-38.76%
Income-92.90M PEG- EPS next Q-0.47 Inst Own84.30% Short Float5.79% Perf Quarter-49.54%
Sales21.40M P/S6.31 EPS this Y2.70% Inst Trans0.12% Short Ratio9.75 Perf Half Y-53.52%
Book/sh1.69 P/B1.29 EPS next Y-29.80% ROA-40.60% Target Price16.29 Perf Year-82.12%
Cash/sh2.35 P/C0.93 EPS next 5Y- ROE-78.00% 52W Range2.24 - 13.64 Perf YTD-33.13%
Dividend- P/FCF- EPS past 5Y-3.60% ROI-62.90% 52W High-84.02% Beta1.83
Dividend %- Quick Ratio5.10 Sales past 5Y116.50% Gross Margin- 52W Low-2.90% ATR0.24
Employees103 Current Ratio5.10 Sales Q/Q50.00% Oper. Margin- RSI (14)22.26 Volatility7.86% 8.20%
OptionableYes Debt/Eq0.38 EPS Q/Q2.80% Profit Margin- Rel Volume1.19 Prev Close2.26
ShortableYes LT Debt/Eq0.38 EarningsNov 05 BMO Payout- Avg Volume350.51K Price2.18
Recom1.90 SMA20-32.06% SMA50-39.68% SMA200-54.37% Volume416,633 Change-3.54%
Nov-04-20Upgrade H.C. Wainwright Neutral → Buy $11 → $15
Sep-22-20Initiated Alliance Global Partners Buy $18
Jan-17-20Downgrade Wedbush Outperform → Neutral
Mar-08-19Resumed JMP Securities Mkt Outperform $18
Feb-14-19Resumed Oppenheimer Outperform $13
Nov-05-18Upgrade ROTH Capital Neutral → Buy
Mar-13-18Reiterated Wedbush Outperform $11 → $13
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jan-10-22 07:00AM  
Dec-28-21 08:53AM  
Nov-16-21 07:30AM  
Nov-05-21 08:55AM  
07:30AM  
Oct-29-21 11:37AM  
07:30AM  
Oct-28-21 03:05PM  
Oct-13-21 04:01PM  
Oct-12-21 08:00AM  
Oct-01-21 02:07AM  
Sep-30-21 02:07PM  
Sep-29-21 08:00AM  
Sep-28-21 04:01PM  
Sep-27-21 08:00AM  
Sep-20-21 03:56PM  
11:30AM  
08:38AM  
Sep-13-21 07:00AM  
Sep-10-21 07:30AM  
Sep-09-21 08:00AM  
Sep-07-21 08:00AM  
Aug-05-21 08:55AM  
07:30AM  
07:15AM  
Jul-29-21 03:05PM  
07:30AM  
Jul-26-21 11:18AM  
Jun-29-21 07:01AM  
Jun-09-21 08:01AM  
Jun-04-21 10:40AM  
May-27-21 11:26AM  
May-19-21 08:31AM  
May-06-21 08:50AM  
07:31AM  
Apr-29-21 08:01AM  
Apr-04-21 09:12PM  
Mar-30-21 06:50AM  
Mar-22-21 11:19AM  
Mar-04-21 10:23AM  
08:55AM  
07:47AM  
07:30AM  
06:30AM  
Feb-25-21 08:01AM  
Feb-22-21 04:30PM  
Jan-26-21 05:32AM  
Jan-19-21 10:41PM  
04:01PM  
Jan-11-21 07:30AM  
Jan-07-21 01:00PM  
Dec-24-20 11:10AM  
Dec-13-20 11:47PM  
Dec-08-20 04:39PM  
Dec-05-20 12:31PM  
12:31PM  
Nov-16-20 08:00AM  
Nov-09-20 10:09AM  
Nov-05-20 04:01PM  
02:30PM  
Nov-04-20 10:26AM  
10:12AM  
Oct-29-20 08:30AM  
Oct-27-20 01:14PM  
Oct-24-20 07:30AM  
Oct-15-20 01:38PM  
Oct-09-20 07:30AM  
Sep-10-20 02:47PM  
08:30AM  
Sep-09-20 08:31AM  
Aug-19-20 08:32AM  
Aug-06-20 09:55AM  
07:31AM  
Aug-05-20 09:09AM  
Jul-30-20 12:34PM  
08:30AM  
Jul-07-20 08:00AM  
Jul-05-20 02:45PM  
Jun-17-20 08:00AM  
Jun-15-20 06:31AM  
Jun-11-20 08:31AM  
May-29-20 08:01AM  
May-28-20 08:00AM  
May-19-20 07:22AM  
May-13-20 05:01PM  
May-12-20 10:32AM  
May-08-20 02:31PM  
May-07-20 10:05AM  
08:08AM  
07:30AM  
May-06-20 10:01AM  
Apr-30-20 08:30AM  
Apr-29-20 12:34PM  
Apr-07-20 09:30AM  
Mar-26-20 10:16AM  
Mar-22-20 10:27AM  
Mar-05-20 08:45AM  
07:30AM  
Feb-27-20 12:30PM  
08:00AM  
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Olson Eric RChief Scientific OfficerJan 05Sale3.472,2087,6550Jan 06 05:02 PM
Olson Eric RChief Scientific OfficerMar 15Option Exercise1.013,6283,6643,628Mar 17 05:10 PM
Olson Eric RChief Scientific OfficerMar 15Sale9.473,62834,3720Mar 17 05:10 PM
Young Richard ADirectorFeb 16Sale12.053,75045,188321,711Feb 18 05:34 PM
Young Richard ADirectorFeb 08Sale13.043,75048,900325,461Feb 10 05:29 PM